Added to YB: 2025-12-03
Pitch date: 2025-11-30
NVO [neutral]
Novo Nordisk A/S
+0.41%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.10
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
turnaround
Can They Work Again? - Novo Nordisk A/S
NVO (update): GLP-1 obesity/diabetes market projected >$100B globally next decade. Down on US price negotiations & failed Alzheimer's study, but lower prices = broader gov't patient access potentially offsetting unit price decline. International growth matching US. Author holds 70% 5yr gains, monitoring for consolidation.
Read full article (2 min)